1436 related articles for article (PubMed ID: 26314834)
1. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
Marquez-Medina D; Popat S
Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
[TBL] [Abstract][Full Text] [Related]
2. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
Tan CS; Cho BC; Soo RA
Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
[TBL] [Abstract][Full Text] [Related]
3. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
4. [A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker].
Wislez M; Malka D; Bennouna J; Mortier L; Bensadoun RJ; Sicard J; Dielenseger P; Rey JB; Moro-Sibilot D; Scotté F
Bull Cancer; 2014 Jun; 101(6):647-52. PubMed ID: 24977454
[TBL] [Abstract][Full Text] [Related]
5. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
Heigener DF; Schumann C; Sebastian M; Sadjadian P; Stehle I; Märten A; Lüers A; Griesinger F; Scheffler M;
Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527
[TBL] [Abstract][Full Text] [Related]
6. Afatinib for the treatment of advanced non-small-cell lung cancer.
Genova C; Rijavec E; Barletta G; Burrafato G; Biello F; Dal Bello MG; Coco S; Truini A; Alama A; Boccardo F; Grossi F
Expert Opin Pharmacother; 2014 Apr; 15(6):889-903. PubMed ID: 24646054
[TBL] [Abstract][Full Text] [Related]
7. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
8. Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.
Brückl W; Tufman A; Huber RM
Expert Rev Anticancer Ther; 2017 Feb; 17(2):143-155. PubMed ID: 27898252
[TBL] [Abstract][Full Text] [Related]
9. Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
Landi L; Tiseo M; Chiari R; Ricciardi S; Rossi E; Galetta D; Novello S; Milella M; D'Incecco A; Minuti G; Tibaldi C; Salvini J; Facchinetti F; Haspinger ER; Cortinovis D; Santo A; Banna G; Catino A; GiajLevra M; Crinò L; de Marinis F; Cappuzzo F
Clin Lung Cancer; 2014 Nov; 15(6):411-417.e4. PubMed ID: 25242668
[TBL] [Abstract][Full Text] [Related]
10. Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.
Liao BC; Lin CC; Lee JH; Yang JC
Lung Cancer; 2017 Aug; 110():7-13. PubMed ID: 28676222
[TBL] [Abstract][Full Text] [Related]
11. The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer.
Metro G; Crinò L
Expert Rev Anticancer Ther; 2011 May; 11(5):673-82. PubMed ID: 21554040
[TBL] [Abstract][Full Text] [Related]
12. [Afatinib as first-line therapy in mutation-positive EGFR. Results by type of mutation].
Vidal ÓJ
Med Clin (Barc); 2016 Apr; 146 Suppl 1():12-8. PubMed ID: 27426243
[TBL] [Abstract][Full Text] [Related]
13. Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib.
Hirsh V
BioDrugs; 2015 Jun; 29(3):167-83. PubMed ID: 26123538
[TBL] [Abstract][Full Text] [Related]
14. Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.
van der Wekken AJ; Kuiper JL; Saber A; Terpstra MM; Wei J; Hiltermann TJN; Thunnissen E; Heideman DAM; Timens W; Schuuring E; Kok K; Smit EF; van den Berg A; Groen HJM
PLoS One; 2017; 12(8):e0182885. PubMed ID: 28854272
[TBL] [Abstract][Full Text] [Related]
15. Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer.
Tan F; Shi Y; Wang Y; Ding L; Yuan X; Sun Y
Future Oncol; 2015; 11(3):385-97. PubMed ID: 25675121
[TBL] [Abstract][Full Text] [Related]
16. [Afatinib in patients with squamous cell carcinoma of the lung: current context and the option of oral treatment].
Cobo M; Gutiérrez V; Rodelo L; López O; Ruiz M; Godoy A
Med Clin (Barc); 2016 Apr; 146 Suppl 1():25-9. PubMed ID: 27426245
[TBL] [Abstract][Full Text] [Related]
17. Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer.
Engle JA; Kolesar JM
Am J Health Syst Pharm; 2014 Nov; 71(22):1933-8. PubMed ID: 25349236
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy.
Kanda S; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Kubota K; Tamura T; Ohe Y
Lung Cancer; 2015 Sep; 89(3):287-93. PubMed ID: 26169499
[TBL] [Abstract][Full Text] [Related]
19. Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.
Chen YM; Lai CH; Rau KM; Huang CH; Chang HC; Chao TY; Tseng CC; Fang WF; Chung YH; Wang YH; Su MC; Huang KT; Liu SF; Chen HC; Chang YC; Chang YP; Wang CC; Lin MC
BMC Cancer; 2016 Nov; 16(1):868. PubMed ID: 27821111
[TBL] [Abstract][Full Text] [Related]
20. Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors.
Sun JM; Ahn MJ; Choi YL; Ahn JS; Park K
Lung Cancer; 2013 Nov; 82(2):294-8. PubMed ID: 24035188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
